Long-Term Data Reinforce Standard of Care in Unresectable Melanoma
Jump to navigation
Jump to search
https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.9506
Frontline treatment of unresectable melanoma with the immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) led to an unprecedented median overall survival (OS) of 6 years, an updated analysis of a randomized trial showed.